The pharmacologic therapy of post-cauterization and post-laser vaporization with polydeoxyribonucleotide.
The most widely used ablative techniques in the therapy of benign cervical lesions are physical treatments with cauterization or laser vaporization; these are, however, usually used for the largest or symptomatic lesions. Many Authors suggest, after physical treatment, the use of topical chemotherapy in order to abolish any possible inflammatory reaction. The use of drugs such as polydeoxyribonucleotide (PDRN) 5 mg (POLIDES 5--Farmigea), provided with reepithelialization and anticomplement action, seems to promote a quicker recovery of the cauterized or vaporized zone, avoiding, at the same time, the secondary inflammatory reaction. The Authors have assessed the quality of reepithelialization by means of PDRN 5 mg ovules of the cervical zone which has been previously subjected to laser vaporization or cauterization for benign cervical lesions or CIN I. The trial was performed with two groups of patients: Group A: laser vaporization, 45 patients, 23 of whom treated with PDRN and 22 with placebo. Group B: cauterization, 46 patients, 24 treated with PDRN and 22 with placebo. The treatment with PDRN 5 mg ovules started on the day of physical treatment and continued for twelve days. The examination of the patients, performed before the treatment (TO) included the following tests: bacteriological test; PAP-smear, colposcopic examination with eventual direct biopsy. The first follow-up (T 1) was performed after 14 days and included a Pap-smear, colposcopic examination and microcolpohysteroscopy (MC) carried out in the zone where physical treatment had been performed, in order to obtain a map of the reepithelialization process process.(ABSTRACT TRUNCATED AT 250 WORDS)
Perino
A
A
Obstetric and Gynecologic Clinic of Physiopathology of the Reproduction, University of Palermo, Italy.
Genova
G
G
Vita
C
C
Costa
P
P
Biondo
A
A
Palmeri
M A
MA
Filippazzo
G
G
D002425:Cautery; D003127:Colposcopy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D053685:Laser Therapy; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D002577:Uterine Cervical Diseases / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D011089:Polydeoxyribonucleotides